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SUMMARY
Pleomorphic sarcoma is the most common sarcoma.  Reports
of outcome as well as evaluation of prognostic factors in the
literature show great variation.  We looked at our experience
in treating this tumour at University Malaya Medical Center.
This is a review of patients diagnosed with Pleomorphic
Sarcoma from January 1990 to December 2005 at University
Malaya Medical Center.  Outcome measures studied are the
overall survival, disease free survival and local recurrence of
disease.  Prognostic factors for survival and local recurrence
which were studied are the tumour size, depth, stage, type
of surgery, adjuvant therapy, and surgical margin.  There
were fifty four patients available for analysis of
demographics.  The mean age at presentation was 52.3 ± 16.7
years.  There were thirty male patients (56%) and twenty
four female patients (44%) in the study population.  The
patients were predominantly Malay (44.4%) and Chinese
(42.6%).  There were two Indian patients (3.7%) and five
patients from other races (9.3%).  Thirty patients had disease
affecting the extremities while six patients had disease
affecting the trunk.  Patients with tumour affecting the trunk
had 100% mortality.  In patients with tumour affecting the
extremity, 46.7% presented with Stage 3 disease.  The overall
median survival was 39 months.  The overall survival rate at
3 years was 53.3% and the 5 years was 30.0%.  The disease
free survival rate at five years was 27.6%.   However, if
patients who presented with metastasis were excluded, the
5 year survival rate was 60% while the disease free survival
was 53.3%.  Recurrence rate was 33.3%.  Factors affecting
survival was stage, size and location of tumour.  No factors
were found to correlate with higher local recurrence rate.  In
conclusion, Pleomorphic Sarcoma is a heterogenous disease
with variable outcome.  In our centre, late presentation with
advanced disease significantly affects the overall outcome of
this condition.  Tumour size and location are important
prognostic factors.  Inherent tumour behavior and
aggressiveness probably outweigh current treatment
modalities as the most important prognostic factor in the
management of Pleomorphic Sarcoma.
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INTRODUCTION
Ever since its first description in 1964, the histopathologic
entity of Pleomorphic sarcoma or previously known as
Malignant Fibrous Histiocytoma (MFH), has been surrounded
with controversies 1.  Variations in diagnostic criteria as well
as the presence of different subtypes add to its confusion.
However, through the years, it has emerged as the most
common soft tissue sarcoma as reported in most published
literature 2, 3, 4. Earlier reports of the outcome of this disease
revealed poor prognosis with about 30 percent survival rate at
5 years5.   However, more recent reports have reported an
improvement in the survival rate for these patients 6, 7.  A
multitude of prognostic factors have also been shown to
affect outcome but there is a lack of consistency with
different reports stating different prognostic factors.  Apart
from the tumour behaviour, patient factors such as the time
of presentation have been shown to affect the overall
survival.  So far, no literature has been published with regards
to the outcome of this tumour and factors affecting its
prognosis in this region. Therefore, we wish to report on the
long-term outcome of patients presenting with Pleomorphic
Sarcoma and its possible prognostic factor in patients
managed in the University Malaya Medical Center.
MATERIALS AND METHODS
This is a review of patients diagnosed with Malignant Fibrous
Histiocytoma or Pleomorphic Sarcoma from January 1990 to
December 2005 in University Malaya Medical Center.  The
particulars of the patients were obtained from the
histopathological database of the Department of Pathology.
During the period of the study, fifty-four patients were
diagnosed with either Malignant Fibrous Histiocytoma or
Pleomorphic Sarcoma.  However, only thirty six patients had
complete admission records, histopathological examination
reports and valid contact numbers to ascertain the final
outcome of the disease.  In this pool of thirty-six patients,
thirty had involvement of the extremities and six patients
had involvement of the trunk and thorax. These two groups
of patients were analysed separately.
The outcome measures analysed include the disease free
survival as well as local recurrence of the disease. Disease free
survival was defined as patients who were still alive without
clinical evidence of local recurrence or metastatic disease at the
time of review (1st December 2007).  Local recurrence of the
disease was defined as reappearance of the tumour at the
primary surgical site after complete excision of the tumour.
This recurrence was proven by histopathological examination.
The prognostic factors studied were:
1. Tumour size: Obtained from macroscopic examination of
the tumour and is defined as the maximal linear
dimension of the tumour.
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2. Tumour depth: Tumours are deemed superficial when
they are located superficial to the deep fascia and deep
seated if they are located deep to the deep fascia.
3. Stage of disease: Patients are staged using Computed
Tomography of the chest (CT Chest), Magnetic Resonance
Imaging (MRI) where available, Bone Scintigraphy where
available and are classified according to Enneking’s
classification 8. 
4. Metastasis at presentation is defined as presence of distant
spread discovered within three months of presentation.
5. Administration of Adjuvant therapy: In addition to the
surgery, the effect of chemotherapy and radiotherapy was
analysed.
6. Type of surgical intervention: Either limb sparing surgery
with wide resection of the tumour or ablative surgery by
amputation was performed in this group of patients 9.
7. Margins: As determined by pathologist through
microscopic examination. Either all the margins of the
tumour are clear of tumour or there is contamination with
tumour.
The statistical analysis of the data was carried out with SPSS
version 13.0.  Survivorship of patients was illustrated using
Kaplan Meier survivorship study as well as survival at three
years and five years. The significance of the prognostic factors
was analysed using Chi- Square test with significance set at
95% confidence limit.
RESULTS
There were fifty four patients available for analysis of
demographics.   However, subsequent analysis of outcome
and prognostic factors will only include thirty six patients
with complete records. 
The mean age at presentation was 52.3 ± 16.7 years.  There were
thirty male patients (56%) and twenty four female patients
(44%).  The patients were predominantly Malay (44.4%) and
Chinese (42.6%). There were only two Indian patients (3.7%)
and five patients from other ethnic groups (9.3%).
The analysis was done separately for the two groups.  The first
group included patients who had disease involving the trunk
and thorax.  There were six patients in this group. They had
100% mortality rate with a median survival of 4.5 months.
The locations of the tumour were the lung in one patient, the
pelvis in three patients and the retroperitoneal space in two
patients, as shown in Table I. Four (66.7%) of these cases were
inoperable tumours due to the location and size of the
tumour.
The second group of patients had tumours involving the
extremities. In this group, the patients presented at a mean
duration of 9.8 ± 11.7 months after appearance of the
swelling.  At the time of excision, the mean tumour size was
12.7 ± 6.3cm in its maximal dimension.  Ninety percent of
the tumours were purely soft tissue tumour and there were
three cases (10%) that involved the bone. Eighty percent were
located deep to the deep fascia while twenty percent were
superficial.  In terms of tumour histology, Chart 1 shows the
distribution of the various subtypes. The commonest form
encountered was the pleomorphic type, followed by the
myxoid type. 
In terms of stage of disease at presentation, 46.7% of patients
presented with Stage 3 disease (with metastasis).  The tumour
was limited to one compartment in 16.7% of cases and had
extended to more than one compartment in 36.7% of cases.
All the tumours were reported as high grade tumour (Grade
3). 
Surgically, nineteen patients underwent wide resection
(63.3%) and eleven patients (36.7%) underwent amputation
above the level of the disease.   There was one patient with
bone MFH that underwent wide resection and endoprosthetic
replacement.  The surgical margins were clear in 76.7% of
cases. 43.3% of these patients received adjuvant
chemotherapy while 13.3% of patients had adjuvant
radiotherapy. The others did not receive any form of adjuvant
treatment.  The adjuvant chemotherapy given was
Doxorubicin and Ifosfamide.
The overall median survival was thirty-nine months.  The
three years survival rate was 53.3% while at 5 years, the
survival was 30.0%.  The disease free survival rate at five years
was 27.6%.  However, if patients who presented with
metastasis were excluded, the five years survival rate was 60%
while the disease free survival rose to 53.3%.  Chart 2 shows
the Kaplan Meier survivorship for this group of thirty
patients. 
We found that only two of the factors analysed were
statistically significant; (a) metastasis at presentation and (b)
tumour size.  The median survival for patients without
metastasis was seventy seven months while those with
metastasis had a median survival of thirteen months.  As
mentioned earlier, 46.7% of patients had metastasis at
presentation.   In the group that presented without metastatic
disease, five eventually developed metastasis.  The median
duration for appearance of metastatic disease was thirty three
months.  Chart 3 depicts the difference in survival between
those who had metastasis and those who did not have
metastatic disease at presentation.
Our study showed that tumour size significantly affected the
outcome.  The difference in survivorship of tumours less than
ten centimeters compared to tumours ten centimeters or
more is depicted in Chart 4.  Smaller tumour size at
presentation gave a better outcome. Other factors such as
deep-seated tumours, extra-compartmental disease,
recurrence, positive surgical margin, type of surgical
procedure and administration of adjuvant therapy did not
affect survival significantly in our study.
Recurrence occurred at a rate of 33.3%. Statistical analysis did
not reveal any significant factors which affected the
recurrence rate. The factors that we analysed were surgical
margin, tumour depth, compartment status, the surgical
procedure done, tumour size and postoperative radiotherapy.




Table I: Site of axial tumour 
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DISCUSSION
Since the description of Malignant Fibrous Histiocytoma as
an entity in 1964, it was soon realized that some of the
previous diagnosis of Pleomorphic Liposarcoma or
Fibrosarcoma could actually have been Malignant Fibrous
Histiocytoma1. The discovery of this tumour was soon
followed by various subtyping and this created greater
uncertainty as to tumour behaviour and prognosis 10.
However, Pleomorphic Sarcoma (MFH) soon emerged as the
commonest soft tissue sarcoma in most published literature
with this tumour comprising thirty to forty eight percent of
all soft tissue sarcomas 2,3,4,11.  Gutierrez in a large review of
8249 soft tissue sarcoma reported that Malignant Fibrous
Histiocytoma constituted 31.5% of all soft tissue sarcoma12.
This tumour has also been reported to involve not only the
soft tissue of limbs but also the bone and lungs 13,14. 
Most published literatures on outcome as well as prognostic
factors showed this tumour to be a heterogenous entity with
variable survival rates as well as prognostic factors.  Belal in a
retrospective review of 109 cases of Pleomorphic Sarcoma
quoted a relapse free survival rate of 39% at five years and
36% at ten years 15.   This is comparable to the figures quoted
by Bertoni in his publication in 1985 whereby the five year
survival rate was 36%5.  This is in contrast with other reports
which quoted survival rates of up to 70% 6, 7, 16, 17.  Most of these
studies excluded patients who had metastasis at presentation.
In our series, we defined metastasis at presentation as patients
who demonstrated distant spread within three months of
presentation. This is because the surgical excision often
preceded computed tomography of the chest and bone scan.
Hence, the staging could have been delayed. Secondly almost
half the patients in our series presented at a very late stage
and therefore, would not give a true reflection as to the
overall prognosis of this tumour if treated early.  When these
patients were analysed, the disease free survival was only
27.6%.  If patients with metastasis at presentation were
excluded, the overall survival rate rose to sixty percent while
the disease free survival was 53.3%. The vast difference in
outcome is most likely a reflection of the inherent nature of
this tumour.  Its response to systemic chemotherapy is not as
established as seen in the treatment of Osteosarcoma and
Ewing’s sarcoma.
Fig. 1: Histological subtypes of Malignant Fibrous Histiocytoma Fig. 2: Survivorship curve for patients with Malignant Fibrous
Histiocytoma affecting the appendicular skeleton
Fig. 3: Comparison of survivorship between patients with
metastasis and those without
Fig. 4: Comparison of survivorship between tumour less than
10cm and tumours 10cm or more
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Analysis of prognostic factor in our series showed that apart
from the presence of metastatic disease, tumour size and
location was the only other significant factors in affecting
survival.  Tumours affecting the pelvis, retroperitoneal space
and lung have uniformly poor outcome in our study.
However, tumour size is the most consistent prognostic factor
affecting survival with various publications reporting similar
findings 5, 7, 17.   Zagars in a review of 271 patients with
Pleomorphic Sarcoma reported that the factors which affected
metastatic recurrence were tumour size more than 10cm as
well as myxoid type histological subtype18.  Other prognostic
factors which have been reported to be important in survival
were tumour grade, tumour depth, a more proximal location
of the tumour and surgical margin 5, 7, 16, 17, 18.
The significance of local recurrence in the overall outcome of
soft tissue tumours has been debated. Ueda T in 1997
reported the significance of local recurrence as a prognostic
factor.  He reported that local recurrence after definitive
surgery was an important factor but local recurrence at
presentation was not19.  However, Gustafsson et al reported
that patients who had local recurrence without metastatic
disease were considered to have good prognosis with a five
year metastasis free survival rate of 73%4.   In our study, cross
tabulation between the occurrence of recurrence and
outcome was not statistically significant. This probably shows
that the prognosis of Pleomorphic sarcoma is determined by
the presence of systemic disease as with most tumours.
In our study, no significant factors were found to affect the
rate of recurrence.  One particularly surprising finding was
that even positive surgical margin did not influence the
recurrence rate.  This is in contrast with most publications
which quoted this as one of the more consistent factors in
determining the occurrence of local recurrence 5, 7, 11.  Tanabe
concluded that possible factors which might contribute to
this were more liberal definition of positive margins,
inclusion of tumours with low grade behaviour, and a shorter
follow up duration 20.  In our study, probably the most
important factor was the survival of patients was too short to
detect recurrence as we had included patients who have
metastatic disease at presentation.   If these patients were
excluded, our sample might also be too small to generate any
significant conclusion regarding the effect of positive surgical
margin on local recurrence.  Other important prognostic
factors for local recurrence which have been described are
depth of tumour and postoperative radiotherapy.
In conclusion, Pleomorphic sarcoma is a heterogenous
disease with variable outcome.  In our set up, late
presentation significantly affects the overall outcome of this
disease due to advanced disease at presentation.  Tumour size
and location are important prognostic factors.  Inherent
tumour behaviour and aggressiveness probably outweigh
current treatment modalities as the more important
prognostic factors in the management of Pleomorphic
Sarcoma.
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